ArticlePathogens (Basel, Switzerland)2020
Evaluation of Nucleoside Analogs as Antimicrobials Targeting Unique Enzymes in
Article in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- Structural basis for selective thymidine binding by the Borrelia burgdorferi substrate-binding protein BmpA.The Journal of biological chemistry · 2026Article
- Current and emerging approaches for eliminatingFrontiers in microbiology · 2024Review
- Metabolic modeling predicts unique drug targets inmSystems · 2023Article
- Screening for small molecule inhibitors of SAH nucleosidase using an SAH riboswitch.Analytical biochemistry · 2023Article
- Pathway Driven Target Selection inFrontiers in cellular and infection microbiology · 2022Article
- Controlling Lyme Disease: New Paradigms for Targeting the Tick-Pathogen-Reservoir Axis on the Horizon.Frontiers in cellular and infection microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
The first line therapy for Lyme disease is treatment with doxycycline, amoxicillin, or cefuroxime. In endemic regions, the persistence of symptoms in many patients after completion of antibiotic treatment remains a major healthcare concern. The causative agent of Lyme disease is a spirochete,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.